Related by context. All words. (Click for frequent words.) 75 imatinib Gleevec 75 tyrosine kinase inhibitors 74 EGFR tyrosine kinase inhibitors 73 anticancer therapy 72 tyrosine kinase inhibitor 72 anti angiogenic agents 72 anticancer therapies 71 MEK inhibitors 71 erlotinib Tarceva 71 BRAF mutation 71 Gleevec resistant 70 erlotinib Tarceva ® 70 PARP inhibitors 70 T#I [002] 70 VEGF inhibitors 70 epithelial tumors 70 NNRTIs 70 receptor tyrosine kinase inhibitor 69 K ras mutations 69 chemotherapeutic agents 69 dasatinib Sprycel 69 EGFr 69 SERMs 69 pertuzumab 69 IGF 1R 69 mTOR inhibitors 69 molecularly targeted 69 proteasome inhibitors 69 Trastuzumab 69 Gefitinib 69 FLT3 69 Dasatinib 69 HuLuc# 68 gefitinib Iressa 68 HDAC inhibitors 68 Imatinib 68 gemcitabine Gemzar 68 imatinib Gleevec ® 68 gastrointestinal stromal tumors GIST 68 Gleevec imatinib 68 anti angiogenic drugs 68 trans retinoic acid 68 alkylating agent 68 immunosuppressive therapies 68 Erlotinib 68 dasatinib 68 Symadex 68 TKIs 68 TNF inhibitors 68 proteasome inhibitor 68 Akt activation 68 calcineurin inhibitors 68 fulvestrant 68 histone deacetylases 68 anticancer agents 68 endocrine therapies 68 EGFR pathway 68 multitargeted 68 BRAF inhibitor 68 imatinib resistance 68 androgen receptor AR 68 relapsed SCLC 68 imatinib 68 PLX# 68 EGFR inhibition 68 CYT# potent vascular disrupting 68 GIST tumors 68 EGFR mutations 67 EGFR mutation 67 Bortezomib 67 VAPRISOL 67 antiangiogenic therapy 67 nucleoside analogues 67 imatinib resistant 67 chemotherapeutic drug 67 metastatic renal cell carcinoma 67 vascular disrupting agents 67 idarubicin 67 gefitinib 67 cediranib 67 VEGF receptor 67 HCV protease inhibitors 67 thalidomide Thalomid 67 hypereosinophilic syndrome 67 imatinib mesylate 67 bevacizumab Avastin ® 67 kinase inhibitors 67 EGFR tyrosine kinase inhibitor 67 carcinoid 67 mycophenolate mofetil 67 activating mutations 67 cytotoxic chemotherapy 67 gastrointestinal stromal tumors 67 MetMAb 67 TTR gene 67 MMP inhibitors 67 mitochondrial toxicity 67 cetuximab Erbitux 67 NF kB pathway 67 insulin sensitizers 67 chemotherapeutic drugs 67 Gleevec imatinib mesylate 67 mutated KRAS gene 67 PDGFR 67 Ceflatonin 67 NS4A 67 myelofibrosis polycythemia vera 66 antimetabolite 66 visilizumab 66 CCX# 66 PI3K inhibitor 66 alpha interferons 66 PXD# 66 nucleoside analogs 66 KIT mutations 66 HER2 positive metastatic breast 66 rituximab Rituxan 66 TKI therapy 66 hormonal therapies 66 myeloproliferative diseases 66 deacetylase inhibitors 66 EGFR TKIs 66 TNF α 66 LHRH antagonists 66 Herceptin trastuzumab 66 AEG# 66 EGF receptor 66 standard chemotherapy regimens 66 relapsed ovarian cancer 66 Epidermal Growth Factor Receptor 66 CD# antibody [001] 66 Xanafide 66 KRAS mutation 66 c MET 66 JAK inhibitors 66 oral prodrug 66 sorafenib Nexavar 66 ENMD # 66 enzastaurin 66 echinocandins 66 hormone refractory 66 DFMO 66 recurrent glioblastoma multiforme 66 KRAS mutations 66 chemopreventive agent 66 WT1 66 T#I mutation 66 Virulizin ® 66 vandetanib 66 Zolinza 66 mRCC 66 efalizumab 66 LPA1 receptor 66 TNFα 66 lapatinib Tykerb 66 pegylated interferons 66 CCR2 66 OHR/AVR# 66 alefacept 66 LHRH 66 tyrosine kinase inhibitors TKIs 66 HCV protease 66 angiogenesis inhibitor 66 hedgehog pathway 66 OPAXIO 66 pediatric acute lymphoblastic 66 ixabepilone 66 antisense inhibitors 65 immune modulating 65 chemotherapeutic agent 65 peptide antigens 65 chronic eosinophilic leukemia 65 dexrazoxane 65 obatoclax 65 EpCAM 65 mapatumumab 65 TNF inhibitor 65 antiproliferative effects 65 luteinizing hormone releasing 65 HER2 receptor 65 differentiated thyroid 65 adriamycin 65 taxane therapy 65 Traficet EN 65 imatinib therapy 65 interferon IFN 65 cetuximab Erbitux ® 65 predictive biomarkers 65 chemoresistance 65 multidrug resistance 65 protease inhibitors 65 Aurora kinase 65 Epratuzumab 65 MyVax R 65 Lenalidomide 65 Smac mimetic 65 metaglidasen 65 bevacizumab Avastin 65 Vandetanib 65 PDGF receptor 65 somatostatin analogue 65 cisplatin chemotherapy 65 IGF IR 65 dasatinib Sprycel ® 65 Talabostat 65 thrombopoietin 65 taxanes 65 SGS# 65 myeloma cells 65 BRAF V#E mutation 65 endothelin receptor antagonists 65 PDE4 inhibitors 65 therapeutic regimens 65 chemotherapeutics 65 Tarvacin 65 EGFR TKI 65 Anthracyclines 65 androgen independent 65 taxane chemotherapy 65 Novartis Gleevec 65 anti EGFR antibody 65 immunosuppressive agents 65 apoptotic pathway 65 microtubule targeting 65 SUTENT 65 decitabine 65 nilotinib Tasigna 65 Everolimus 65 humanized antibody 65 AT1R 65 gastrointestinal stromal tumor GIST 65 EGFR antibodies 65 Fludara 65 cytoprotective 65 targeting CD# 65 DACH platinum 65 kinase inhibition 65 HDAC inhibition 65 cytotoxic agents 65 ADPKD 65 panobinostat 65 HGS ETR1 65 TNF alpha inhibitors 65 signal transduction inhibitors 65 Aliskiren 65 metastatic RCC 65 nilotinib 65 HER2 overexpression 65 XmAb# 65 lenalidomide dexamethasone 65 polymerase inhibitors 65 castration resistant prostate cancer 65 docetaxel Taxotere ® 65 JAK2 inhibitors 65 Akt inhibitor 65 N Myc 65 pan HDAC inhibitor 65 GPNMB 65 talabostat 65 gastrointestinal stromal tumors GISTs 65 iniparib 65 TNF á 65 Aflibercept 65 glucagon receptor 65 recurrent glioblastoma 65 chemopreventive agents 65 bortezomib Velcade 65 VEGF pathway 65 nucleoside analog 65 biologic therapy 65 chronic lymphocytic leukemia CLL 65 vidofludimus 65 alkylating agents 65 hematological malignancy 65 EGF receptors 65 fibrotic disease 65 BMS # 65 ganetespib 65 Bevacizumab 65 Vorinostat 64 protein kinase inhibitor 64 trastuzumab Herceptin ® 64 malignant pleural mesothelioma 64 osteosarcomas 64 endostatin 64 Alemtuzumab 64 TNFa 64 pro angiogenic 64 Squalamine 64 bleomycin 64 vWD 64 PI3 kinase 64 chemosensitivity 64 basal cell carcinoma BCC 64 Tyrima 64 Epothilones 64 CCR5 antagonists 64 pancreatic adenocarcinoma 64 angiogenesis inhibitors 64 metastatic neuroendocrine tumors 64 xenograft models 64 selective modulator 64 HGS ETR2 64 ZOLINZA 64 Velcade bortezomib 64 anti angiogenic therapy 64 immunosuppressive regimens 64 leukemia ALL 64 cMET 64 histone deacetylase inhibitors 64 oncoproteins 64 pomalidomide 64 IMC A# 64 JAK3 64 OXi# 64 S/GSK# 64 Src inhibitors 64 APTIVUS r 64 renal toxicity 64 vemurafenib 64 tumor vasculature 64 lung fibrosis 64 alvespimycin 64 DMARDS 64 PRT# 64 Tamibarotene 64 vinca alkaloids 64 atypical hemolytic uremic syndrome 64 LHRH agonists 64 cilengitide 64 CA4P 64 elotuzumab 64 metastatic melanomas 64 cabazitaxel 64 ovarian carcinoma 64 bicalutamide 64 chemotherapeutic 64 Fludarabine 64 CLL cells 64 neurotrophic 64 OncoVEX GM CSF 64 Pertuzumab 64 Hsp# inhibition 64 leukemia AML 64 lipid lowering therapies 64 PARP inhibition 64 signal transduction inhibitor 64 Interferon alpha 64 radezolid 64 CBLC# 64 vascular disrupting agent 64 mutational status 64 anti VEGF 64 nucleoside analogue 64 itraconazole 64 antiangiogenic 64 CCR5 antagonist 64 mutated BRAF gene 64 uric acid lowering 64 vorinostat 64 FGFR1 64 A3 adenosine receptor 64 antiandrogens 64 chemokine receptor 64 Blinatumomab 64 hypomethylating agents 64 Tarceva erlotinib 64 amrubicin 64 ponatinib 64 chemoresistant 64 angiogenesis inhibition 64 leukaemias 64 Proxinium TM 64 Tumor Necrosis Factor 64 demethylating agent 64 cyclin E 64 intravenous bisphosphonates 64 seliciclib 64 HBeAg negative 64 LHRH analogues 64 galiximab 64 interferon alfa 64 anemias 64 histologies 64 topotecan 64 Corticosteroids 64 tumor necrosis 64 MET amplification 64 neuroendocrine cancers 64 anthracyclines 64 anti androgen 64 IFN beta 64 Carfilzomib 64 rhIL 7 64 paclitaxel Taxol 64 tumor subtypes 64 Amplimexon 64 VEGFR2 64 tocilizumab 64 anti angiogenic agent 64 azacytidine 64 Targretin 64 Doxil ® 64 CTLA 4 64 TNF alpha antagonist 64 flavopiridol 64 investigational therapies 64 small molecule inhibitors 64 PARP inhibitor 64 INCB# [001] 64 cetuximab Erbitux R 64 tafamidis 64 anticancer treatments 64 ErbB2 64 vinca alkaloid 64 myeloproliferative disorders 64 sunitinib Sutent 64 Abatacept 64 motesanib 64 breast cancer subtypes 64 leukemic stem cells 64 5 HT3 receptor 64 BCR ABL inhibitors 64 EGFRvIII 64 metastatic malignant 64 antiestrogen 64 GISTs 64 carcinoids 64 microglial activation 63 echinocandin 63 glitazones 63 inhibiting tumor 63 Pseudomonas aeruginosa infections 63 PI3K inhibitors 63 superficial bladder cancer 63 immunomodulatory therapy 63 neuroblastomas 63 gemcitabine carboplatin 63 chlorambucil 63 panitumumab Vectibix 63 NKG2D 63 gastrointestinal stromal tumor 63 posaconazole 63 antitumor 63 Bcr Abl inhibitors 63 Protease inhibitors 63 Deforolimus 63 Sorafenib 63 pharmacokinetic interactions 63 metastatic malignant melanoma 63 oblimersen 63 BRAF gene 63 Fludara ® 63 Mitoxantrone 63 endothelin receptor 63 TrkA 63 brostallicin 63 colorectal carcinoma 63 Factor VIIa 63 Bcr Abl mutations 63 preclinically 63 MGd 63 effector function 63 bone metastasis 63 adrenergic receptors 63 serotonin receptor 63 sorafenib tablets 63 CD# antibodies 63 Nexavar ® 63 Enbrel Humira 63 unresectable tumors 63 anti leukemic 63 clodronate 63 HbF 63 non metastatic osteosarcoma 63 castrate resistant prostate cancer 63 Rituximab 63 ADAM# 63 myelosuppression 63 mTOR inhibitor 63 BRAF inhibitors 63 epithelial cancers 63 p# activation 63 TTF Therapy 63 myeloid 63 hepatocellular cancer 63 hematologic malignancies 63 FOLFIRINOX 63 humanized monoclonal antibody 63 Enzastaurin 63 regorafenib 63 oncogenesis 63 YONDELIS 63 cisplatin resistant 63 direct thrombin inhibitors 63 Temsirolimus 63 M2 subunit 63 oral JAK1 63 TNF antagonist 63 AMN# [001] 63 multiple myeloma MM 63 IL 1ß 63 tanespimycin 63 alpha interferon 63 temsirolimus 63 mycosis fungoides 63 mGluR5 antagonist 63 prostate carcinoma 63 gemifloxacin 63 Voreloxin 63 humanized anti 63 Hsp# inhibitors 63 Hepatocellular Carcinoma HCC 63 BCR ABL protein 63 bortezomib 63 EBV infection 63 EP1 receptor 63 chronic myelogenous leukemia CML 63 castrate resistant 63 EGFR 63 Aplidin 63 refractory gout 63 Genentech Rituxan 63 immunomodulation 63 PTP 1B 63 antitumor effect 63 IgG1 antibody 63 dacarbazine 63 systemically administered 63 MAGE A3 ASCI 63 Sutent sunitinib 63 raltegravir 63 investigational humanized monoclonal antibody 63 EGFR receptor 63 Golimumab 63 JAK2 63 corticosteroid therapy 63 prognostic markers 63 pharmacologic intervention 63 enzyme inhibitor 63 malignant ascites 63 cancer immunotherapies 63 Nexavar sorafenib 63 cell lymphoma CTCL 63 GRN# 63 virotherapy 63 beta adrenergic 63 aromatase inhibitors AIs 63 KRAS status 63 HSP# inhibitor 63 5 HT2B receptor 63 Amrubicin 63 Vidofludimus 63 systemic fungal infections 63 #HT#A 63 Nilotinib 63 TG# [003] 63 TGF β 63 virologic responses 63 metastatic colorectal 63 ALK inhibitor 63 CRTH2 63 nonmelanoma skin cancers 63 FOLFIRI 63 trabectedin 63 receptor inhibitor 63 Panzem R NCD 63 trastuzumab Herceptin 63 cytostatic 63 elvucitabine 63 Smac mimetics 63 IAP inhibitors 63 BCR ABL 63 IMA# 63 EndoTAGTM 1 63 E#F# 63 PEGylated Fab fragment 63 goserelin 63 ISF# 63 MGUS 63 EGFR inhibitor 63 INCB# [003] 63 nephrotoxicity 63 ADAMTS# 63 renal fibrosis 63 Seliciclib 63 calcineurin inhibitor 63 interferon therapy 63 PKC# 63 Treg cell 63 HDACi 63 Azedra 63 efaproxiral 63 idraparinux 63 related apoptosis inducing 63 humanised monoclonal antibody 63 adefovir 63 cidofovir 63 BRAF V# mutation 63 chemotherapeutic regimens 63 compound AEZS 63 denileukin diftitox 63 nilotinib Tasigna ® 63 inhibitor RG# 63 Revlimid lenalidomide 63 radiation sensitizer 63 tyrosine kinase inhibitor TKI 63 Factor Receptor 63 TYZEKA 63 TOP2A 63 sodium glucose cotransporter 63 receptor antagonists 63 essential thrombocythemia 63 angiotensin converting enzyme inhibitors 63 erythropoietic 63 GSK3B 63 Campath alemtuzumab 63 cardiotoxic 63 Alequel 63 dexamethasone Decadron 63 Helicobacter pylori H. pylori 63 NFkB 63 mecamylamine 63 somatostatin receptors 63 lymphoid malignancies 63 5 HT6 receptor 63 XYOTAX TM 63 Panitumumab 63 liver metastases 63 VA# [002] 63 depsipeptide 63 dopaminergic therapy 63 TroVax ® 63 Sym# 62 HuMax CD4 62 Elotuzumab 62 Calcitonin 62 pegfilgrastim 62 conventional chemotherapies 62 immunomodulatory therapies 62 fluoropyrimidine 62 immune modulator 62 hormone LHRH antagonist 62 CYC# 62 Doxorubicin 62 ErbB3 62 histone deacetylase inhibitor 62 menadione 62 RANK ligand 62 NAbs 62 Romidepsin 62 malignant transformation 62 refractory chronic myeloid 62 kinase inhibitor 62 familial amyloidotic polyneuropathy FAP 62 Factor Xa inhibitor 62 trastuzumab 62 anti CD3 62 NRTIs 62 neovascular diseases 62 PROCHYMAL 62 SMAD4 62 Telintra 62 Eculizumab 62 mGluR2 NAM 62 biologic therapies 62 neuroprotectant 62 hepatic toxicity 62 tumor antigen 62 ERBB2 62 EGFR HER2 62 invasive candidiasis 62 Crizotinib 62 pDCs 62 TNF Tumor Necrosis Factor 62 factor Xa 62 investigational monoclonal antibody 62 Anthracycline 62 Rituxan rituximab 62 canakinumab 62 conventional DMARDs 62 Mitomycin C 62 relapsing MS 62 alpha folate receptor 62 pegylated liposomal doxorubicin 62 neuropilin 62 Pemetrexed 62 Wnt signaling pathway 62 p# MAP kinase 62 antiarrhythmic 62 TRAIL receptor antibodies 62 sJIA 62 Vectibix monotherapy 62 forodesine 62 situ CIS 62 antihormonal 62 Dapagliflozin 62 Hedgehog inhibitor 62 neoadjuvant chemotherapy 62 IV bisphosphonates 62 eIF 4E 62 Irinotecan 62 tipranavir ritonavir 62 TREANDA 62 Taxol ® 62 Avastin Tarceva 62 cetuximab 62 hematological indications 62 ADP receptor antagonist 62 Apaziquone 62 pediatric malignancies 62 OMP #M# 62 anti fibrotic 62 anthracycline chemotherapy 62 anti TNFs 62 paricalcitol 62 B7 H3 62 antisense oligonucleotides 62 ALK inhibitors 62 pimecrolimus 62 selective inhibition 62 immunomodulatory 62 histone deacetylase HDAC 62 sorafenib Nexavar ® 62 androgen deprivation 62 Vidaza azacitidine 62 androgen receptor signaling 62 metastatic kidney 62 delayed CINV 62 peritoneal carcinomatosis 62 serous ovarian cancer 62 Pralatrexate 62 haematological malignancies 62 signaling cascades 62 Cytoxan 62 Surgical resection 62 HBeAg positive 62 myelodysplastic myeloproliferative diseases 62 DMARD 62 elacytarabine 62 cathepsins 62 bexarotene 62 LY# [003] 62 metastatic gastric 62 Th2 cytokines 62 TTR amyloidosis 62 Ocrelizumab 62 metastatic lesions 62 cell malignancies 62 infliximab Remicade 62 neuroendocrine tumors 62 Boceprevir 62 CDK inhibitor 62 Olaparib 62 Tasimelteon 62 melatonin receptor 62 soluble receptor 62 kidney urologic 62 BAY #-# 62 JAK inhibitor 62 Romiplostim 62 nucleosides 62 ErbB3 HER3 62 colorectal liver metastases 62 Beta catenin pathway 62 leukemia CLL 62 TELINTRA 62 phosphate S1P 62 tezampanel 62 antithrombotics 62 hematological cancers 62 Vidaza ® 62 Perifosine 62 fluvastatin 62 PPAR gamma agonists 62 unresectable stage 62 sorafenib 62 Decitabine 62 DOXIL 62 recurrent NSCLC 62 anti apoptotic proteins 62 hematologic disorders 62 GBM tumors 62 lung metastasis 62 hepatotoxicity 62 TNFalpha 62 taxol 62 gastric cancers 62 antiangiogenic agent 62 Stat5 62 OMNARIS HFA 62 Naive Patients 62 ErbB2 positive 62 Reverset 62 antifibrotic 62 mutated KRAS 62 leflunomide 62 chimeric monoclonal antibody 62 HCV replication 62 MEK ERK 62 acute promyelocytic leukemia APL 62 benign prostatic hypertrophy BPH 62 antimetabolites 62 antisense inhibition 62 mTOR mammalian target 62 EphA2 62 riociguat 62 tipranavir 62 proteasome inhibitor bortezomib 62 baseline LDH 62 beta interferons 62 lumiliximab 62 Vaprisol 62 BCR ABL mutations 62 anticholinergics 62 Allovectin 7 ® 62 irinotecan oxaliplatin 62 DMARDs 62 multi kinase inhibitor 62 Cloretazine 62 Amigal 62 molecular abnormalities 62 antibody mediated 62 TNF antagonists 62 palliative radiotherapy 62 microtubule inhibitor 62 plasma kallikrein 62 colony stimulating factors 62 skeletal metastases 62 Epstein Barr virus EBV 62 Bisphosphonate 62 favorable pharmacokinetic profile 62 thymidylate synthase 62 AGILECT R 62 transgene expression 62 protein tyrosine phosphatase 1B 62 apremilast 62 immunomodulator 62 nonalcoholic steatohepatitis NASH 62 CYP #A# 62 vinorelbine 62 rFVIIa 62 basiliximab 62 tNOX 62 Bezielle 62 SCH # 62 COX2 62 CTAP# Capsules 62 refractory metastatic 62 leukemic cells 62 proto oncogene 62 glatiramer 62 GRN#L 62 Celecoxib 62 reperfusion injury 62 Myelodysplastic syndromes MDS 62 ifosfamide 62 Bcr Abl 62 pancreatic neuroendocrine tumors 62 diabetic kidney 62 nutlin 3a 62 HBeAg positive patients 62 tamoxifen Nolvadex ® 62 demethylating agents 62 metastatic castration resistant 62 CHOP chemotherapy 62 CCR9 62 tigecycline 62 Denufosol 62 Myelodysplastic Syndrome MDS 62 GnRH agonists 62 PREZISTA r 62 AGTR1 62 octreotide LAR 62 Torisel 62 EOquin 62 costimulatory 62 glioblastoma tumors 62 FTY# 62 gastric adenocarcinoma 62 HGS# 62 docetaxel chemotherapy 62 sunitinib malate 62 HDAC 62 Imprime PGG 62 triptans 62 premalignant lesions 61 resolvins 61 thymic carcinoma 61 erlotinib 61 PEGylated anti 61 enzyme inhibitors 61 molecular biomarkers 61 BRAF mutations 61 immunomodulators 61 lupus nephritis 61 CYP#A# substrate 61 underlying pathophysiology 61 antiplatelet therapies 61 cholinesterase inhibitors 61 MAPK pathway 61 stage IIIB 61 IAP inhibitor 61 ERK signaling 61 hematopoietic malignancies 61 docetaxel Taxotere R 61 pyridostigmine 61 ara C 61 antiangiogenic agents 61 Pegylated Interferon 61 CXCR4 receptor 61 Bcl xL 61 SPRYCEL ® 61 Telbivudine 61 MUC1 61 Peginterferon alfa 2b 61 azoles 61 Notch1 61 PI3K/mTOR 61 palifermin 61 Inhaled corticosteroids 61 Taxol paclitaxel 61 Estrogen Receptor 61 Glucocorticoids 61 BRCA deficient 61 ErbB 61 atacicept 61 ACZ# 61 histological subtype 61 trastuzumab Herceptin R 61 thrombin receptor 61 irinotecan chemotherapy 61 gamma secretase inhibitor 61 haematologic 61 prognostic marker 61 romidepsin 61 anticancer agent 61 EGFR protein 61 sulfasalazine 61 aromatase inhibitor therapy 61 NKT cells 61 pancreatic NET 61 Hedgehog pathway 61 mu opioid receptor antagonist 61 teriflunomide 61 small molecule tyrosine 61 nanoviricide 61 HCV infection 61 epothilones 61 NXL# 61 Insegia 61 anakinra 61 Apo2L 61 Gleevec 61 ruboxistaurin 61 Cisplatin 61 aminoglycosides 61 calcitriol 61 PPARγ 61 PI3K Akt 61 TRAIL induced apoptosis 61 SCCHN 61 hepatocellular carcinoma HCC 61 aflibercept VEGF Trap 61 Methylnaltrexone 61 ATL# [001] 61 HQK 61 intravenous cyclophosphamide 61 pre malignant lesions 61 alpha 2a 61 #ME# 61 T#I mutant 61 treating neuropathic pain 61 RNAi therapeutic targeting 61 vWF 61 overlapping toxicities 61 protease inhibitor 61 oncolytic 61 otelixizumab 61 PDE5 inhibitors 61 CMV disease 61 HER2/neu 61 prostate cancer CRPC 61 hyperalgesia 61 muscarinic 61 estrogen receptor beta 61 neoplastic cells 61 HMG CoA reductase inhibitors 61 Leukemias 61 anti mitotic 61 MYLOTARG 61 glioma cells 61 LY# [002] 61 interferons 61 PTPN# 61 NS#/#A protease 61 etanercept Enbrel 61 DU #b 61 cranial irradiation